Evaluation of DCTclock™ as a Cognitive Assessment Aid

March 5, 2018 updated by: Digital Cognition Technologies
The overall objective of this study is to demonstrate the safety and effectiveness of DCTclock as an adjunctive tool for use by clinicians to evaluate cognitive function in adults aged 55-95.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

450

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Florida
      • Maitland, Florida, United States, 32751
        • Compass Research

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

51 years to 91 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Men and women 55 to 95 years old.

Exclusion Criteria:

  • Ineligible for written informed consent.
  • Physical impairment of the writing hand.
  • Impaired manual dexterity.
  • Impaired vision.
  • Under the influence of recreational drugs or alcohol at the time of the visit.
  • Current or recent participation in a clinical trial that includes the use of a drug or intervention to alter cognitive function.
  • Recent cognitive testing.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: All qualified participants
Participants received DCTclock, Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and a battery of other traditional pen and paper neuropsychological assessments.
DCTclock is a quick and non-invasive test that measures cognitive function based on a computerized algorithmic analysis of the entire drawing process and output of a well-established cognitive assessment called The Clock Drawing Test (CDT).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Non-Inferiority of DCTclock Compared to Mini-Mental State Examination (MMSE)
Time Frame: Visit 1 (day 1)
The primary analysis will assess agreement between DCTclock and the Montreal Cognitive Assessment (MoCA) and compare it to the agreement between the MMSE and MoCA at visit 1.
Visit 1 (day 1)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quadratic Weighted Kappa on Primary Endpoints
Time Frame: Visit 1 (day 1)
Quadratic weighted Cohen's kappa with 95% CI between DCTclock and MoCA, as well as between MMSE and MoCA.
Visit 1 (day 1)
Percent Agreement on Primary Endpoints
Time Frame: Visit 1 (day 1)
Positive percent agreement, version A (treating the "Indeterminate" group as "Unimpaired") and version B (removing the "Indeterminate" group from the analysis), and negative percent agreement version A and version B. These were calculated for the DCTclock/MoCA classification table as well as the MMSE/MoCA classification table. 95% CI were also calculated and compared between the two classification tables' calculations.
Visit 1 (day 1)
Regression Coefficients on Primary Endpoints
Time Frame: Visit 1 (day 1)
Linear and rank-linear regression coefficients (slope, intercept) and 95% CI for DCTclock regressed on MoCA as well as for the MMSE regressed on MoCA.
Visit 1 (day 1)
Correlation Coefficients on Primary Endpoints
Time Frame: Visit 1 (day 1)
Pearson and Spearman correlation coefficients between DCTclock and MoCA as well as between MMSE and MoCA.
Visit 1 (day 1)
Quadratic Weighted Kappa on Secondary Endpoints (Test-Retest Reliability)
Time Frame: Visit 1 and visit 2, occurring 1-4 weeks apart
Quadratic weighted Cohen's Kappa statistics were calculated for both DCTclock and MMSE test-retest data (visit 1 vs visit 2).
Visit 1 and visit 2, occurring 1-4 weeks apart
Percent Agreement on Secondary Endpoints (Test-retest Reliability)
Time Frame: Visit 1 and visit 2, occurring 1-4 weeks apart
Positive percent agreement version A (treating the "Indeterminate" group as "Unimpaired") and version B (removing the "Indeterminate" group from the analysis), negative percent agreement version A and version B, indeterminate percent agreement, and unimpaired percent agreement.
Visit 1 and visit 2, occurring 1-4 weeks apart
Regression Coefficients on Secondary Endpoints (Test-retest Reliability)
Time Frame: Visit 1 and visit 2, occurring 1-4 weeks apart
Deming, linear, and rank-linear correlation coefficients (intercept, slope) were calculated for visit 1 regressed on visit 2 for both DCTclock and MMSE.
Visit 1 and visit 2, occurring 1-4 weeks apart
Correlation Coefficients on Secondary Endpoints (Test-retest Reliability)
Time Frame: Visit 1 and visit 2, occurring 1-4 weeks apart
Pearson and Spearman correlation coefficients were calculated between visit 1 and visit 2 for DCTclock and MMSE, along with 95% CI.
Visit 1 and visit 2, occurring 1-4 weeks apart

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Construct Validity of DCTclock as Measured by the Comparison of DCTclock Results to the Results of a Battery of Neuropsychological Assessments
Time Frame: Visit 1 (day 1)
The goal of this analysis is to assess the construct validity of DCTclock. Specifically, the goal is to compare scores from the administration of DCTclock to the visit 1 administration of a battery of neuropsychological tests, to characterize the psychometric properties of DCTclock, and to compare those properties to the properties of MMSE.
Visit 1 (day 1)
Incidence of Serious Device-related Adverse Events [Safety]
Time Frame: Visit 1 and visit 2, occuring 1-4 weeks apart
Incidence of serious device-related adverse events.
Visit 1 and visit 2, occuring 1-4 weeks apart

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Antonia H Holway, Ph.D., Digital Cognition Technologies, Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 11, 2017

Primary Completion (Actual)

November 21, 2017

Study Completion (Actual)

November 21, 2017

Study Registration Dates

First Submitted

July 27, 2017

First Submitted That Met QC Criteria

July 31, 2017

First Posted (Actual)

August 3, 2017

Study Record Updates

Last Update Posted (Actual)

April 3, 2018

Last Update Submitted That Met QC Criteria

March 5, 2018

Last Verified

March 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • DCT032

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

We do not plan to share IPD

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cognitive Function

Clinical Trials on DCTclock

Subscribe